Case-Based Roundtable Meetings Spotlight April 2, 2021

Pashna N. Munshi, MD, discussed the case of a 48-year-old male patient with acute graft-versus-host-disease.

Jaffer A. Ajani, MD led a discussion around biomarkers to consider when determining systemic therapy for patients with stage IV gastric adenocarcinoma.

During a virtual Targeted Oncology Case-Based Roundtable event, Michael A. Carducci, MD, reviewed the results of the CARD trial to support his recommendation of cabazitaxel for the treatment of a 75-year-old man with metastatic castration-resistant prostate cancer.

The DECISION and SELECT studies provide evidence of response to multikinase inhibitors after disease progression in patients with thyroid carcinoma.

Corey J. Langer, MD, led a peer discussion around novel targets for adjuvant non–small cell lung therapy.

The PROfound and TRITON2 clinical trials have demonstrated the benefit of the PARP inhibitors olaparib and rucaparib for the treatment of metastatic castration-resistant prostate cancer.

Helen Moon, MD, reviewed the data from the JAVELIN Bladder 100 trial, which support the use of avelumab as maintenance therapy for patients with metastatic bladder cancer.

Luis Raez, MD, Hdiscussed the case of a 59-year-old patient with RET-mutated lung cancer.

During a Targeted Oncology Case-Based Roundtable event, Joseph Mikhael, MD, discusses responses observed in transplant-eligible patients with multiple myeloma.

David Dingli, MD, PhD, discussed the case of a 51-year-old patients with transplant-eligible myeloma.

During a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.

Matthew Smith, MD, PhD, discussed the new hormone therapies entering the treatment landscape for metastatic castration-resistant prostate cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.